Connection

Brent Egan to Blood Pressure

This is a "connection" page, showing publications Brent Egan has written about Blood Pressure.
Connection Strength

9.567
  1. Hypertension Control in the United States 2009 to 2018: Factors Underlying Falling Control Rates During 2015 to 2018 Across Age- and Race-Ethnicity Groups. Hypertension. 2021 09; 78(3):578-587.
    View in: PubMed
    Score: 0.482
  2. The global burden of hypertension exceeds 1.4 billion people: should a systolic blood pressure target below 130 become the universal standard? J Hypertens. 2019 06; 37(6):1148-1153.
    View in: PubMed
    Score: 0.418
  3. Adherence in Hypertension. Circ Res. 2019 03 29; 124(7):1124-1140.
    View in: PubMed
    Score: 0.413
  4. Improving Hypertension Control in Primary Care With the Measure Accurately, Act Rapidly, and Partner With Patients Protocol. Hypertension. 2018 12; 72(6):1320-1327.
    View in: PubMed
    Score: 0.404
  5. Hypertension in african americans aged 60 to 79 years: statement from the international society of hypertension in blacks. J Clin Hypertens (Greenwich). 2015 Apr; 17(4):252-9.
    View in: PubMed
    Score: 0.312
  6. Diabetes and age-related demographic differences in risk factor control. J Am Soc Hypertens. 2014 Jun; 8(6):394-404.
    View in: PubMed
    Score: 0.295
  7. Response to Comment on optimal treatment for resistant hypertension: the missing data on pulse wave velocity. Hypertension. 2014 Mar; 63(3):e17-8.
    View in: PubMed
    Score: 0.291
  8. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension. 2013 Oct; 62(4):691-7.
    View in: PubMed
    Score: 0.279
  9. Blood pressure and cholesterol control in hypertensive hypercholesterolemic patients: national health and nutrition examination surveys 1988-2010. Circulation. 2013 Jul 02; 128(1):29-41.
    View in: PubMed
    Score: 0.278
  10. Associations among environmental supports, physical activity, and blood pressure in African-American adults in the PATH trial. Soc Sci Med. 2013 Jun; 87:108-15.
    View in: PubMed
    Score: 0.272
  11. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension. 2012 Jun; 59(6):1124-31.
    View in: PubMed
    Score: 0.256
  12. Renal sympathetic denervation: a novel intervention for resistant hypertension, insulin resistance, and sleep apnea. Hypertension. 2011 Oct; 58(4):542-3.
    View in: PubMed
    Score: 0.244
  13. Is blood pressure control to less than 140/less than 90 mmHg in 50% of all hypertensive patients as good as we can do in the USA: or is this as good as it gets? Curr Opin Cardiol. 2011 Jul; 26(4):300-7.
    View in: PubMed
    Score: 0.242
  14. DASH lowers blood pressure in obese hypertensives beyond potassium, magnesium and fibre. J Hum Hypertens. 2010 Apr; 24(4):237-46.
    View in: PubMed
    Score: 0.211
  15. Pleiotropic benefits of moderate salt reduction. Hypertension. 2009 Sep; 54(3):447-8.
    View in: PubMed
    Score: 0.211
  16. Sleep-disordered breathing and blood pressure in children. Hypertension. 2008 Nov; 52(5):807.
    View in: PubMed
    Score: 0.200
  17. Dietary salt restriction and blood pressure in clinical trials. Curr Hypertens Rep. 2007 Aug; 9(4):314-9.
    View in: PubMed
    Score: 0.184
  18. Mechanism of lipid enhancement of alpha1-adrenoceptor pressor sensitivity in hypertension. J Hypertens. 2006 Jul; 24(7):1383-9.
    View in: PubMed
    Score: 0.171
  19. Controlling blood pressure in 50% of all hypertensive patients: an achievable goal in the healthy people 2010 report? J Investig Med. 2003 Nov; 51(6):373-85.
    View in: PubMed
    Score: 0.142
  20. Reproducibility of BP responses to changes in dietary salt: compelling evidence for universal sodium restriction? Hypertension. 2003 Oct; 42(4):457-8.
    View in: PubMed
    Score: 0.140
  21. DASH diet lowers blood pressure and lipid-induced oxidative stress in obesity. Hypertension. 2003 Mar; 41(3):422-30.
    View in: PubMed
    Score: 0.135
  22. Single-pill combinations, hypertension control and clinical outcomes: potential, pitfalls and solutions. Blood Press. 2022 12; 31(1):164-168.
    View in: PubMed
    Score: 0.133
  23. Medication Adherence and Blood Pressure Control: A Scientific Statement From the American Heart Association. Hypertension. 2022 01; 79(1):e1-e14.
    View in: PubMed
    Score: 0.123
  24. The pressor response to acute hyperlipidemia is enhanced in lean normotensive offspring of hypertensive parents. Am J Hypertens. 2001 Oct; 14(10):1032-7.
    View in: PubMed
    Score: 0.123
  25. Baseline Heart Rate Predicts the Blood Pressure Response to Renal Denervation in Untreated Hypertension. J Am Coll Cardiol. 2021 09 07; 78(10):1039-1041.
    View in: PubMed
    Score: 0.122
  26. Nonesterified fatty acids in blood pressure control and cardiovascular complications. Curr Hypertens Rep. 2001 Apr; 3(2):107-16.
    View in: PubMed
    Score: 0.119
  27. Sociodemographic Determinants of Life's Simple 7: Implications for Achieving Cardiovascular Health and Health Equity Goals. Ethn Dis. 2020; 30(4):637-650.
    View in: PubMed
    Score: 0.115
  28. Antihypertensive Treatment in Elderly Frail Patients: Evidence From a Large Italian Database. Hypertension. 2020 08; 76(2):330-332.
    View in: PubMed
    Score: 0.113
  29. The prevalence of concurrently raised blood glucose and blood pressure in India. J Hypertens. 2019 09; 37(9):1788-1789.
    View in: PubMed
    Score: 0.106
  30. Optimal Systolic Blood Pressure Target in Resistant Hypertension. Am J Med. 2019 07; 132(7):e623.
    View in: PubMed
    Score: 0.105
  31. Prognostic value of blood pressure control delay in newly diagnosed hypertensive patients. J Hypertens. 2019 02; 37(2):290-291.
    View in: PubMed
    Score: 0.102
  32. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018 11; 72(5):e53-e90.
    View in: PubMed
    Score: 0.100
  33. Cost-Utility of an Objective Biochemical Measure to Improve Adherence to Antihypertensive Treatment. Hypertension. 2018 11; 72(5):1090-1092.
    View in: PubMed
    Score: 0.100
  34. Intralipid enhances alpha1-adrenergic receptor mediated pressor sensitivity. Hypertension. 1998 Oct; 32(4):693-8.
    View in: PubMed
    Score: 0.100
  35. Defining Hypertension by Blood Pressure 130/80 mm Hg Leads to an Impressive Burden of Hypertension in Young and Middle-Aged Black Adults: Follow-Up in the CARDIA Study. J Am Heart Assoc. 2018 07 14; 7(14).
    View in: PubMed
    Score: 0.098
  36. Trends in Prehypertension and Hypertension Risk Factors in US Adults: 1999-2012. Hypertension. 2017 08; 70(2):275-284.
    View in: PubMed
    Score: 0.091
  37. Systolic Blood Pressure Intervention Trial (SPRINT) and Target Systolic Blood Pressure in Future Hypertension Guidelines. Hypertension. 2016 08; 68(2):318-23.
    View in: PubMed
    Score: 0.085
  38. Blood Pressure Control Provides Less Cardiovascular Protection in Adults With Than Without Apparent Treatment-Resistant Hypertension. J Clin Hypertens (Greenwich). 2016 08; 18(8):817-24.
    View in: PubMed
    Score: 0.083
  39. Elevated blood pressures in obese young men with mild hypertension are sustained during the day and night. Am J Hypertens. 1994 Jul; 7(7 Pt 1):609-14.
    View in: PubMed
    Score: 0.074
  40. Closing the gap in hypertension control between younger and older adults: National Health and Nutrition Examination Survey (NHANES) 1988 to 2010. Circulation. 2014 May 20; 129(20):2052-61.
    View in: PubMed
    Score: 0.073
  41. Insulin levels are similar in obese salt-sensitive and salt-resistant hypertensive subjects. Hypertension. 1994 Jan; 23(1 Suppl):I1-7.
    View in: PubMed
    Score: 0.072
  42. Decreased heart rate variability is associated with increased transcranial Doppler velocities in children with sickle cell disease. Ethn Dis. 2014; 24(4):451-5.
    View in: PubMed
    Score: 0.072
  43. Epithelial sodium channel inhibition by amiloride on blood pressure and cardiovascular disease risk in young prehypertensives. J Clin Hypertens (Greenwich). 2014 Jan; 16(1):47-53.
    View in: PubMed
    Score: 0.071
  44. Improved baroreflex sensitivity in elderly hypertensives on lisinopril is not explained by blood pressure reduction alone. J Hypertens. 1993 Oct; 11(10):1113-20.
    View in: PubMed
    Score: 0.071
  45. Blood pressure reclassification in adolescents based on repeat clinic blood pressure measurements. J Clin Hypertens (Greenwich). 2013 Oct; 15(10):717-22.
    View in: PubMed
    Score: 0.070
  46. Different definitions of prevalent hypertension impact: the clinical epidemiology of hypertension and attainment of Healthy People goals. J Clin Hypertens (Greenwich). 2013 Mar; 15(3):154-61.
    View in: PubMed
    Score: 0.067
  47. Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial. Cardiovasc Ther. 2010 Dec; 28(6):344-9.
    View in: PubMed
    Score: 0.058
  48. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010 May 26; 303(20):2043-50.
    View in: PubMed
    Score: 0.056
  49. Antihypertensive medication prescribing patterns in a university teaching hospital. J Clin Hypertens (Greenwich). 2010 Apr; 12(4):246-52.
    View in: PubMed
    Score: 0.055
  50. Low-Sodium DASH reduces oxidative stress and improves vascular function in salt-sensitive humans. J Hum Hypertens. 2009 Dec; 23(12):826-35.
    View in: PubMed
    Score: 0.052
  51. Effects of ketanserin on blood pressure and platelet aggregation in elderly men with mild hypertension. Am J Hypertens. 1988 Jul; 1(3 Pt 3):324S-330S.
    View in: PubMed
    Score: 0.049
  52. Combination therapy with an angiotensin-converting enzyme inhibitor and a calcium channel blocker. J Clin Hypertens (Greenwich). 2007 Oct; 9(10):783-9.
    View in: PubMed
    Score: 0.047
  53. Use of statins and blood pressure. Am J Hypertens. 2007 Sep; 20(9):937-41.
    View in: PubMed
    Score: 0.046
  54. Cardiovascular risk factor control in communities--update from the ASH Carolinas-Georgia Chapter, the Hypertension Initiative, and the Community Physicians' Network. J Clin Hypertens (Greenwich). 2006 Dec; 8(12):879-86.
    View in: PubMed
    Score: 0.044
  55. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension. 2006 Mar; 47(3):345-51.
    View in: PubMed
    Score: 0.041
  56. Challenges and risks in attaining the systolic blood pressure goal of <130 mm Hg in all diabetic patients. J Clin Hypertens (Greenwich). 2006 Jan; 8(1):50-2.
    View in: PubMed
    Score: 0.041
  57. Platelet and white blood cell counts are elevated in patients with the metabolic syndrome. J Clin Hypertens (Greenwich). 2005 Dec; 7(12):705-11; quiz 712-3.
    View in: PubMed
    Score: 0.041
  58. Prevalence, treatment, and control of chest pain syndromes and associated risk factors in hypertensive patients. Am J Hypertens. 2005 Aug; 18(8):1026-32.
    View in: PubMed
    Score: 0.040
  59. Prehypertension and cardiovascular morbidity. Ann Fam Med. 2005 Jul-Aug; 3(4):294-9.
    View in: PubMed
    Score: 0.040
  60. Metabolic syndrome and insulin resistance in the TROPHY sub-study: contrasting views in patients with high-normal blood pressure. Am J Hypertens. 2005 Jan; 18(1):3-12.
    View in: PubMed
    Score: 0.039
  61. Prehypertension and mortality in a nationally representative cohort. Am J Cardiol. 2004 Dec 15; 94(12):1496-500.
    View in: PubMed
    Score: 0.038
  62. A systematic approach to managing hypertension and the metabolic syndrome in primary care. South Med J. 2004 Oct; 97(10):932-8.
    View in: PubMed
    Score: 0.038
  63. Angiotensin receptor blockade improves arterial distensibility and reduces exercise-induced pressor responses in obese hypertensive patients with the metabolic syndrome. Am J Hypertens. 2004 Jun; 17(6):477-82.
    View in: PubMed
    Score: 0.037
  64. A statewide primary care approach to cardiovascular risk factor control in high-risk diabetic and nondiabetic patients with hypertension. J Clin Hypertens (Greenwich). 2004 Jan; 6(1):18-25.
    View in: PubMed
    Score: 0.036
  65. TIME to face the reality about evening dosing of antihypertensive drugs in hypertension. Blood Press. 2023 Dec; 32(1):1-3.
    View in: PubMed
    Score: 0.036
  66. Cardiovascular risk factor control and treatment patterns in primary care. Manag Care Interface. 2003 Nov; 16(11):21-6.
    View in: PubMed
    Score: 0.036
  67. Hemodynamic effects of nicotinic acid infusion in normotensive and hypertensive subjects. Am J Hypertens. 2003 Jan; 16(1):67-71.
    View in: PubMed
    Score: 0.034
  68. Masked hypertension in type 2 diabetes: never take normotension for granted and always assess out-of-office blood pressure. Blood Press. 2022 12; 31(1):207-209.
    View in: PubMed
    Score: 0.033
  69. Blood Pressure Control Among Non-Hispanic Black Adults Is Lower Than Non-Hispanic White Adults Despite Similar Treatment With Antihypertensive Medication: NHANES 2013-2018. Am J Hypertens. 2022 Jun 16; 35(6):514-525.
    View in: PubMed
    Score: 0.032
  70. Proceedings From a National Heart, Lung, and Blood Institute and the Centers for Disease Control and Prevention Workshop to Control Hypertension. Am J Hypertens. 2022 03 08; 35(3):232-243.
    View in: PubMed
    Score: 0.032
  71. Hemodynamic effects of lipids in humans. Am J Physiol Regul Integr Comp Physiol. 2001 Jun; 280(6):R1674-9.
    View in: PubMed
    Score: 0.030
  72. Acute physical and mental stress resulted in an increase in fatty acids, norepinephrine, and hemodynamic changes in normal individuals: A possible pathophysiological mechanism for hypertension-Pilot study. J Clin Hypertens (Greenwich). 2021 04; 23(4):888-894.
    View in: PubMed
    Score: 0.029
  73. Nonesterified fatty acids in the pathogenesis of hypertension: theory and evidence. Prostaglandins Leukot Essent Fatty Acids. 1997 Jul; 57(1):57-63.
    View in: PubMed
    Score: 0.023
  74. Adverse effects of short-term, very-low-salt diets in subjects with risk-factor clustering. Am J Clin Nutr. 1997 02; 65(2 Suppl):671S-677S.
    View in: PubMed
    Score: 0.022
  75. Blood pressure and metabolic responses to moderate sodium restriction in isradipine-treated hypertensive patients. Am J Hypertens. 1997 Jan; 10(1):68-76.
    View in: PubMed
    Score: 0.022
  76. Relationship between risk factor control and vascular events in the SAMMPRIS trial. Neurology. 2017 Jan 24; 88(4):379-385.
    View in: PubMed
    Score: 0.022
  77. Trial of stress reduction for hypertension in older African Americans. II. Sex and risk subgroup analysis. Hypertension. 1996 Aug; 28(2):228-37.
    View in: PubMed
    Score: 0.021
  78. Abnormalities of Anthropometric, Hemodynamic, and Autonomic Variables in Offspring of Hypertensive Parents. J Clin Hypertens (Greenwich). 2016 09; 18(9):942-8.
    View in: PubMed
    Score: 0.021
  79. Obesity hypertension is related more to insulin's fatty acid than glucose action. Hypertension. 1996 Mar; 27(3 Pt 2):723-8.
    View in: PubMed
    Score: 0.021
  80. Glucose metabolism in abdominally obese hypertensive and normotensive subjects. Hypertension. 1995 Jul; 26(1):186-92.
    View in: PubMed
    Score: 0.020
  81. Renin and aldosterone are higher and the hyperinsulinemic effect of salt restriction greater in subjects with risk factors clustering. Am J Hypertens. 1994 Oct; 7(10 Pt 1):886-93.
    View in: PubMed
    Score: 0.019
  82. The efficacy and safety of intravenous hydralazine for the treatment of hypertension in the hospitalized child. Pediatr Nephrol. 2014 Aug; 29(8):1403-9.
    View in: PubMed
    Score: 0.018
  83. In prehypertension leukocytosis is associated with body mass index but not with blood pressure or incident hypertension. J Hypertens. 2014 Feb; 32(2):251-9.
    View in: PubMed
    Score: 0.018
  84. Effect of omega-3 fatty acids on the vascular response to angiotensin in normotensive men. Am J Cardiol. 1992 Nov 15; 70(15):1347-52.
    View in: PubMed
    Score: 0.017
  85. NaCl induces differential changes of regional vascular reactivity in salt-sensitive versus salt-resistant men. Am J Hypertens. 1991 Dec; 4(12 Pt 1):924-31.
    View in: PubMed
    Score: 0.016
  86. Office and ambulatory blood pressure-lowering effects of combination valsartan/hydrochlorothiazide vs. hydrochlorothiazide-based therapy in obese, hypertensive patients. J Clin Hypertens (Greenwich). 2011 Oct; 13(10):731-8.
    View in: PubMed
    Score: 0.015
  87. Comparative effects of overweight on cardiovascular risk in younger versus older men. Am J Cardiol. 1991 Feb 01; 67(4):248-52.
    View in: PubMed
    Score: 0.015
  88. Potential deleterious impact of dietary salt restriction on cardiovascular risk factors. Klin Wochenschr. 1991; 69 Suppl 25:45-50.
    View in: PubMed
    Score: 0.015
  89. Angiotensin receptor blocker/diuretic combination preserves insulin responses in obese hypertensives. J Hypertens. 2010 Aug; 28(8):1761-9.
    View in: PubMed
    Score: 0.014
  90. Artefacts in measurement of blood pressure and lack of target organ involvement in the assessment of patients with treatment-resistant hypertension. Ann Intern Med. 1990 Feb 15; 112(4):270-7.
    View in: PubMed
    Score: 0.014
  91. Importance of overweight in studies of left ventricular hypertrophy and diastolic function in mild systemic hypertension. Am J Cardiol. 1989 Oct 01; 64(12):752-5.
    View in: PubMed
    Score: 0.013
  92. Sustained saline-induced secretion of atrial natriuretic hormone is not maintained by atrial stretch. J Clin Endocrinol Metab. 1989 Apr; 68(4):735-9.
    View in: PubMed
    Score: 0.013
  93. The importance of hemodynamic considerations in essential hypertension. Am Heart J. 1988 Aug; 116(2 Pt 2):594-9.
    View in: PubMed
    Score: 0.012
  94. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens. 2008 Mar; 26(3):589-99.
    View in: PubMed
    Score: 0.012
  95. Effect of a high-fiber diet vs a fiber-supplemented diet on C-reactive protein level. Arch Intern Med. 2007 Mar 12; 167(5):502-6.
    View in: PubMed
    Score: 0.011
  96. The heart and the regulation of renin. Circulation. 1987 Jan; 75(1 Pt 2):I130-3.
    View in: PubMed
    Score: 0.011
  97. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006 Apr 20; 354(16):1685-97.
    View in: PubMed
    Score: 0.010
  98. Pharmacologic reduction of sympathetic drive increases platelet alpha-2-receptor number. Clin Pharmacol Ther. 1985 Nov; 38(5):519-24.
    View in: PubMed
    Score: 0.010
  99. Nutritional and lifestyle approaches to the prevention and management of hypertension. Compr Ther. 1985 Aug; 11(8):15-20.
    View in: PubMed
    Score: 0.010
  100. Is low-risk hypertension fact or fiction? cardiovascular risk profile in the TROPHY study. Am J Hypertens. 2005 Jul; 18(7):980-5.
    View in: PubMed
    Score: 0.010
  101. Excessive alcohol consumption and hypertension: clinical implications of current research. J Clin Hypertens (Greenwich). 2005 Jun; 7(6):346-51.
    View in: PubMed
    Score: 0.010
  102. Methods for measuring vascular and nonvascular alpha-receptor sensitivity in humans. J Cardiovasc Pharmacol. 1985; 7 Suppl 6:S153-8.
    View in: PubMed
    Score: 0.010
  103. Role of cardiopulmonary mechanoreceptors in ADH release in normal humans. Hypertension. 1984 Nov-Dec; 6(6 Pt 1):832-6.
    View in: PubMed
    Score: 0.010
  104. Elevation of C-reactive protein in people with prehypertension. J Clin Hypertens (Greenwich). 2004 Oct; 6(10):562-8.
    View in: PubMed
    Score: 0.009
  105. Cardiopulmonary mechanoreceptors and renin release in humans. Fed Proc. 1983 Jul; 42(10):2703-8.
    View in: PubMed
    Score: 0.009
  106. Acute hyperlipidemia increases oxidative stress more in African Americans than in white Americans. Am J Hypertens. 2003 May; 16(5 Pt 1):331-6.
    View in: PubMed
    Score: 0.009
  107. Borderline hypertension. Prim Care. 1983 Mar; 10(1):99-113.
    View in: PubMed
    Score: 0.008
  108. Low birth weight as a risk factor for hypertension. J Clin Hypertens (Greenwich). 2003 Mar-Apr; 5(2):133-6.
    View in: PubMed
    Score: 0.008
  109. Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans. Prostaglandins Leukot Essent Fatty Acids. 1999 May-Jun; 60(5-6):401-5.
    View in: PubMed
    Score: 0.006
  110. Relationships among plasma aldosterone, high-density lipoprotein cholesterol, and insulin in humans. Hypertension. 1995 Jan; 25(1):30-6.
    View in: PubMed
    Score: 0.005
  111. Red blood cell Li+-Na+ countertransport, Na+-K+ cotransport, and the hemodynamics of hypertension. Hypertension. 1987 May; 9(5):459-66.
    View in: PubMed
    Score: 0.003
  112. Anger and anxiety in borderline hypertension. Psychosom Med. 1986 Mar-Apr; 48(3-4):242-8.
    View in: PubMed
    Score: 0.003
  113. Reflex-hemodynamic adjustments and baroreflex sensitivity during converting enzyme inhibition with MK-421 in normal humans. Hypertension. 1983 Mar-Apr; 5(2 Pt 2):I184-91.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.